TrialInternational journal of clinical oncology2025

Phase II study of afatinib for advanced non-small cell lung cancer with uncommon epidermal growth factor receptor mutations, including compound mutations detected by next-generation sequencing.

Nobuaki Mamesaya et al.PubMed ↗Publisher ↗

No numbers read from the abstract.